Eli Lilly and Company (NYSE:LLY) Position Increased by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 29,472 shares of the company’s stock after buying an additional 908 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Eli Lilly and Company were worth $17,180,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth about $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the third quarter worth approximately $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company during the third quarter valued at about $40,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on LLY. Morgan Stanley boosted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $3.82 on Monday, hitting $737.33. The stock had a trading volume of 2,726,536 shares, compared to its average volume of 3,017,770. The firm’s 50 day moving average price is $760.89 and its 200-day moving average price is $668.00. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78. The company has a market capitalization of $700.58 billion, a price-to-earnings ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.09 earnings per share. On average, equities research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.